

NIRSEVIMAB

Read in conjunction with [Disclaimer](#)

Formulary: Restricted For use as per WA Immunisation Schedule and WA Health Communicable Disease Control Directorate guidance.	
Presentation	Prefilled Syringe: <ul style="list-style-type: none"> 50 mg in 0.5 mL (purple plunger rod) 100 mg in 1 mL (light blue plunger rod)
Drug Class	Monoclonal antibody immunisation
Indication	<p>Prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease for infants who meet the criteria determined by the Western Australian Immunisation Schedule.</p> <p>Also see decision aid flow charts:</p> <ul style="list-style-type: none"> RSV immunisation decision aid RSV immunisation decision aid - Kimberley and Pilbara regions <p>NOTE: Parent/Guardian consent is to be obtained prior to administration of all vaccinations.</p>
Special Considerations	<ul style="list-style-type: none"> Avoid use in infants less than 1.6 kg and/or less than 29 weeks corrected gestational age. If considering discharge, consult Infectious Diseases (ID) for further advise in these infants. For children undergoing cardiac surgery with cardiopulmonary bypass, an additional dose of nirsevimab is recommended as soon as the child is stable after surgery to ensure adequate nirsevimab serum levels. Refer to the product information for dosing advice. Contraindicated for infants with severe allergy to any ingredients of nirsevimab injection. Caution should be taken with intramuscular injections for children with thrombocytopenia, coagulation disorders or on anticoagulation therapy.
Interactions	<ul style="list-style-type: none"> No interaction studies have been conducted. Interactions with other medications are unlikely. Nirsevimab can be co-administered with other scheduled vaccines. Ensure a different injection site is used.
Incompatibility	The contents of the nirsevimab prefilled syringe should not be combined with any fluids or other vaccinations prior to administration.
Side Effects	Uncommon: rash, injection site reaction (pain, redness, swelling), fever.
Monitoring	<p>Clinically observe the infant for 15 minutes post administration for adverse reaction or anaphylaxis.</p> <p>Saturation and cardiorespiratory monitoring is not required following administration.</p>

Storage & Stability

Refrigerate between 2 to 8°C, do not freeze. Protect from light.

- May be kept at room temperature (below 25°C) for up to 8 hours. If not used within 8 hours, the syringe must be discarded. Do not return to the refrigerator.

INTRAMUSCULAR INJECTION

Presentation

Prefilled Syringe:

- 50 mg in 0.5 mL (purple plunger rod)
- 100 mg in 1 mL (light blue plunger rod)



Dosage

Working Weight

Dose

Less than 5 kg

50 mg (in 0.5 mL)

5 kg and greater

100 mg (in 1 mL)

Nirsevimab should be prescribed for all eligible infants in preparation for discharge from hospital. For healthy full term infants, this may mean administering at the same time as their first dose of Hepatitis B vaccination.

Preparation

- Visually inspect prefilled syringe for particulate matter and discolouration. Nirsevimab should be a clear to opalescent, colourless to yellow solution.
- Remove the syringe cap off the nirsevimab syringe and attach a Luer lock needle.

Administration

Administer the entire contents of the prefilled syringe as an intramuscular injection as per the [Medication Administration Guideline](#).

Related Policies, Procedures, and Guidelines

HDWA Policies and Information:

[Western Australian Immunisation Schedule](#)

[Respiratory Syncytial Virus](#)

[Respiratory Syncytial Virus \(RSV\) immunisation](#)

[Immunisation education](#)

Clinical Practice Guidelines:

[Neonatology - Immunisations](#)

Consumer Information:

[PCH RSV Immunisation for Children Health Facts Sheet](#)

Pharmaceutical and Medicines Management Guidelines:



[WNHS Cold Chain Management for Medications and Vaccines](#)

[CAHS Medication Refrigerators and Freezers](#)

References

AusDI. Beyfortus™ (Nirsevimab) Solution for Injection. In: AusDI By Medical Director [Internet]. Australia: AusDI by Medical Director; 2023 [cited 2024 Mar 20]. Available from: <https://www.ausdi.com/>

Document history

Keywords	Nirsevimab, Beyfortus, immunisation, RSV, respiratory syncytial virus, monoclonal antibody				
Document Owner:	Chief Pharmacist				
Author/ Reviewer	KEMH & PCH Pharmacy/Neonatology Directorate				
Version Info:	V1.0 – Inaugural protocol V1.1 – Updated indication to align with WA Immunisation Schedule (Oct 2024) V1.2 – Decision aid flow charts added (April 2025)				
Date First Issued:	04/04/2024	Last Reviewed:	03/10/2024	Review Date:	03/10/2029
Endorsed by:	Neonatal Directorate Management Group			Date:	29/10/2024
NSQHS Standards Applicable:	<input checked="" type="checkbox"/>  Std 1: Clinical Governance		<input checked="" type="checkbox"/>  Std 4: Medication Safety		
Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from WNHS HealthPoint.					

This document can be made available in alternative formats on request for a person with a disability.

© North Metropolitan Health Service 2024